Evidence map›Paper›PMID 40042553›Full record

ReviewEuropean journal of pediatrics2025

Why think twice before prescribing proton pump inhibitors.

An-Sofie Lemmens, Koen Huysentruyt, Yvan Vandenplas

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

An-Sofie LemmensDepartment of Pediatric Gastroenterology, UZ Brussels, KidZ Health Castle, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090, Brussels, Belgium.
Koen HuysentruytDepartment of Pediatric Gastroenterology, UZ Brussels, KidZ Health Castle, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090, Brussels, Belgium.
Yvan VandenplasDepartment of Pediatric Gastroenterology, UZ Brussels, KidZ Health Castle, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090, Brussels, Belgium. yvan.vandenplas@uzbrussel.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proton pump inhibitors (PPIs) represent a class of drugs most prominently known for their use in acid-related disorders. Omeprazole, a drug belonging to this class, is among the top 10 most prescribed drugs in the USA. PPIs have a direct effect on the gastric pH and therefore on the gastric mucosa. This review aims to present the most common adverse effects PPIs have on the gastric mucosa in particular.

conclusionPPIs affect the composition of gut and gastric microbiota and will eventually modulate the immune response. WHAT IS KNOWN: • Proton-pump inhibitors are amonth the most frequent prescirbed drugs becasue of their well demonstrated efficacy in acid-related disorders. • Because of their mode of action and their metabolism, a large spectrum of adversee effects have been reported. WHAT IS NEW: • Although the well-known success of PPIs in the wide spectrum of all acid-related conditions should not refrain health care professionals to use them when indicated, insufficient attention is given to the multiple adverse effects reported for this class of drugs. • Well designed prospective trials collecting adverse effects are required, since most studies reporting adverse effects are retrospective, are biassed and have methodological issues.

Indexed as

Gastric MucosaProton Pump InhibitorsChildGastrointestinal MicrobiomeHumansOmeprazoleOmeprazoleProton Pump InhibitorsGastric mucosaOmeprazoleProton pump inhibitors

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.